Victory Capital Management Inc. Boosts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Victory Capital Management Inc. raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 13.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,130 shares of the medical equipment provider's stock after buying an additional 10,297 shares during the quarter. Victory Capital Management Inc. owned about 0.13% of Lantheus worth $7,795,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in LNTH. State of New Jersey Common Pension Fund D boosted its holdings in shares of Lantheus by 0.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares during the period. Bleakley Financial Group LLC boosted its holdings in shares of Lantheus by 6.1% in the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after purchasing an additional 129 shares during the period. UMB Bank n.a. boosted its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus in the 3rd quarter worth approximately $25,000. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after purchasing an additional 280 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Remove Ads

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 54,109 shares of company stock valued at $5,105,606. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.54 on Tuesday, reaching $102.22. 518,963 shares of the stock traded hands, compared to its average volume of 939,616. The company has a fifty day moving average price of $92.25 and a 200-day moving average price of $96.67. The company has a market cap of $7.00 billion, a price-to-earnings ratio of 17.01 and a beta of 0.38. Lantheus Holdings, Inc. has a 12 month low of $56.44 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target for the company. JMP Securities reissued a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.